

REMARKS

The cancellation of Claims 10, 21 and 30 are to eliminate redundant claims, following the election of rivastigmine in Claims 9, 20 and 29 in the accompanying Response to Restriction Requirement. No new matter has been added.

Should the Examiner have any questions, please contact the undersigned attorney.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(617) 871-3346



John Prince
Attorney for Applicants
Reg. No. 43,019

Date: March 6, 2007